ProQR Therapeutics (PRQR) Current Leases (2021 - 2025)

ProQR Therapeutics' Current Leases history spans 4 years, with the latest figure at $1.7 million for Q4 2024.

  • For Q4 2024, Current Leases fell 3.57% year-over-year to $1.7 million; the TTM value through Dec 2024 reached $1.7 million, down 3.57%, while the annual FY2024 figure was $1.7 million, 2.86% down from the prior year.
  • Current Leases for Q4 2024 was $1.7 million at ProQR Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.8 million in Q4 2021 and bottomed at $1.4 million in Q4 2022.
  • The 4-year median for Current Leases is $1.7 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Current Leases decreased 19.36% in 2022 before it grew 22.72% in 2023.
  • A 4-year view of Current Leases shows it stood at $1.8 million in 2021, then dropped by 19.36% to $1.4 million in 2022, then rose by 22.72% to $1.7 million in 2023, then dropped by 3.57% to $1.7 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Current Leases are $1.7 million (Q4 2024), $1.7 million (Q4 2023), and $1.4 million (Q4 2022).